A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors

Park, Silvia; Ahn, Myung Ju; Ahn, Jin Seok; Sun, Jong Mu; Shim, Young Mog; Kim, Young Tae; Choi, Yong Soo; Kim, Kwhanmien; Shin, Sumin; Ahn, Yong-Chan; Kwon, O Jung; Kim, Hojoong; Lee, S.J.; Chang, Won Jin; Park, Keunchil

doi:10.1097/jto.0b013e318292c41e

Cited by 33 publications

(21 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, there has been less report of ORR of cisplatin plus docetaxel for patients with metastatic thymoma without MG till now. However, our results was partially consistent with a previous prospective phase II clinical trial carried out in patients with advanced thymic epithelial tumors (Masaoka Stage III/IV) (Park et al 2013). The results showed that all patients achieved partial response or stable disease.…”

Section: Discussionsupporting

confidence: 82%

“…In a subset of patients with thymic carcinoma, 12 patients (67%) achieved partial response and the other 6 achieved stable disease. Meanwhile, 5 patients with thymoma (55.6%) had partial response and the remaining 4 had stable disease (Park et al 2013). A previous study of a 57-year-old man with Masaoka stage III thymic carcinoma showed the stable disease achieved after cisplatin plus docetaxel and irradiation therapy (Momozane et al 2016).…”

Section: Discussionmentioning

confidence: 99%

“…As a third-generation chemotherapy agent, docetaxel showed dramatic clinical activity against epithelial tumors (Gandara et al 2000;Oguri et al 2004;Song et al 2014;Watanabe et al 2015). Combined chemotherapy with docetaxel and cisplatin (docetaxel/cisplatin) in a prospective Phase II trial led to a novel response in patients with advanced thymoma (Park et al 2013). Here, we reported a serial of MG patients who underwent docetaxel plus cisplatin chemotherapy for metastatic thymoma with unresectable conditions or patients' refusal.…”

Section: Introductionmentioning

confidence: 99%

“…Ridwelski et al (2001) reported that a dosage higher than 80 mg/m 2 of docetaxel plus cisplatin was too toxic, and the combination of docetaxel (75 mg/m 2 ) and cisplatin (75 mg/m 2 ) were used for locally advanced and metastatic gastric cancer. Similarly, in a prospective phase II trial of docetaxel/cisplatin in the induction chemotherapy on thymic epithelial tumors, the treatment regimen consisted of docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 (Park et al 2013). Roka and his colleges (2004) Tumor response is defined as complete remission (CR), partial remission (PR), stable disease (SD) and disease progression (PD) according to the WHO criteria (World Health Organization 1979).…”

Section: Subjects and Treatmentmentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma

Liu

Hua

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

The prognosis of myasthenia gravis (MG) in association with invasive or metastatic thymoma is usually worse, and therapeutic options are quite limited. Here, we retrospectively reported the therapeutic effect of docetaxel plus cisplatin (docetaxel/cisplatin) chemotherapy in 7 MG patients with metastatic thymoma. Previously, all patients underwent thymectomy at the first onset of thymoma. After the metastasis of thymoma, none of the patients received thymectomy due to unresectable conditions after surgeon's evaluation for great risk of myasthenic crisis (n = 5) or patients' refusal (n = 2). All patients received docetaxel (75 mg/m 2 ) and cisplatin (70 mg/m 2 ) on day 1 (d1) every 21 days, with the cycle ranging from 1 to 4. After docetaxel/cisplatin chemotherapy, one patient achieved partial response, and 6 with stable disease of the tumors. The clinical symptoms of MG were alleviated in all patients, 2 with complete remission and the other 5 with marked improvement. Myelosuppression was the major adverse event, occurring in 2 patients (grade II and IV). MG relapse occurred in one patient during the follow-up. Our study presented a series of MG patients with metastatic thymoma who underwent docetaxel/cisplatin chemotherapy. Besides the improved/stabilized thymoma, markedly improvement of MG with the tolerable adverse events was achieved. Docetaxel/cisplatin chemotherapy appears to be an effective treatment for selected patients with MG in association with unresectable metastatic thymoma. Further follow-up of these patients and additional subjects will be needed to determine whether the therapeutic benefits are durable.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Subjects and Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma

Liu

Hua

et al. 2017

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Several chemotherapy regimens have been used in this setting, mostly consisting of adriamycin-and/or platin-based multi-agent combinations (table 4, fig. 2) [78][79][80][81][82][83][84][85][86][87][88]. Usually two to four cycles of chemotherapy are administered before imaging reassessment.…”

Section: Chemotherapy Principlesmentioning

confidence: 99%

Thymic epithelial tumours: from basic principles to individualised treatment strategies

Girard¹

2013

Eur Respir Rev

View full text Add to dashboard Cite

Thymic epithelial tumours represent a wide range of anatomical, clinical, histological and molecular malignant entities that may be aggressive and difficult to treat. The histopathological classification distinguishes thymomas from thymic carcinomas. Thymomas may be associated with autoimmune disorders.The management of thymic epithelial tumours is a paradigm of co-operation between clinicians, surgeons and pathologists, from establishing the diagnosis to organising the multimodal therapeutic strategy. Surgery is the mainstay of the curative-intent treatment, as complete resection represents the most significantly favourable prognostic factor on overall survival. In case of invasion of intra-thoracic structures and/or dissemination to the pleura and the pericardium, precluding complete resection to be achieved, primary chemotherapy has been used to reduce the tumour burden, possibly allowing subsequent surgery and/or radiotherapy.Novel strategies are needed, especially for refractory, recurrent tumours and thymic carcinomas, which carry a poor prognosis. Personalised approaches are currently being developed, as potentially ''druggable'' molecular targets are emerging from recent integrated genomic analyses. Along with the large variety of questions relative to the treatment strategy, thymic epithelial tumours represent a model of therapeutic implementation and achievement in orphan thoracic oncology, showing how the advent of new results induces new questions, as well as diversifies further clinical research directions and international collaborative initiatives.

show abstract

Systemic Therapies in Thymic Malignancies

Kaban

2016

Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies

View full text Add to dashboard Cite

A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors

Abstract: Neoadjuvant docetaxel/cisplatin is both feasible and well tolerated, and potentially improves surgical resectability in patients with advanced TETs.

Cited by 33 publications

References 45 publications

Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma

Therapeutic Potential of Docetaxel plus Cisplatin Chemotherapy for Myasthenia Gravis Patients with Metastatic Thymoma

Thymic epithelial tumours: from basic principles to individualised treatment strategies

Systemic Therapies in Thymic Malignancies

Contact Info

Product

Resources

About